[Febrile neutropenia in adult patients with solid tumours: a review of literature toward a rational and optimal management].
Chemotherapy-induced febrile neutropenia represents a frequent emergency and evidence based management of this event remains an exigency for each patient. Appropriate use of antibiotics is mandatory, growth factors have to be proposed according to validated guidelines and benefits and risks of antiobioprophylaxy must be discussed. This review propose to summarize available data on these important questions, with a special focus on this management of febrile neutropenia in daily practice.
Even
C
C
Groupe Hospitalier La Pitié-Salpêtrière, Service d'Oncologie Médicale, Boulevard de l'Hôpital, 75013 Paris, France.
Taillade
L
L
Spano
J-P
JP
Vignot
S
S
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D000075202:Contraindications; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000379:methods; D004630:Emergencies; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000382:microbiology; D011379:Prognosis; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D016179:Granulocyte Colony-Stimulating Factor